Advantage Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Advantage Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-500	Closed	-$1K	–	1065
2016 Q4	$1K	Hold	500	–	–	﹤0.01%	945
2016 Q3	$2K	Hold	500	–	–	﹤0.01%	853
2016 Q2	$2K	Hold	500	–	–	﹤0.01%	813
2016 Q1	$2K	Hold	500	–	–	﹤0.01%	804
2015 Q4	$2K	Hold	500	–	–	﹤0.01%	800
2015 Q3	$2K	Hold	500	–	–	﹤0.01%	773
2015 Q2	$3K	Sell	500 -1,700	-77%	-$10.2K	﹤0.01%	755
2015 Q1	$14K	Buy	2,200 +700	+47%	+$4.04K	0.01%	532
2014 Q4	$9K	Buy	+1,500	New	+$9.14K	0.01%	548

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CRC

Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Advantage Investment Management's ECYT Position: Q1 2017 in Review

Advantage Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2017, closing a stake of 500 shares — an estimated $1K sold.

Advantage Investment Management first reported a position in ECYT in Q4 2014 and held it in 9 quarters. The position peaked at $14K in Q1 2015. 82 funds tracked by Wall St. Rank hold ECYT as of Q1 2017.

Advantage Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
Advantage Investment Management sold 500 Endocyte, Inc. Common Stock shares in Q1 2017, an estimated $1K.
Advantage Investment Management first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 9 quarters.
Advantage Investment Management's Endocyte, Inc. Common Stock position peaked at $14K in Q1 2015.
82 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2017.

Based on Advantage Investment Management's 13F filing for Q1 2017, filed 8 May 2017.